Advertisement
UK markets close in 1 hour 4 minutes
  • FTSE 100

    8,054.07
    +13.69 (+0.17%)
     
  • FTSE 250

    19,567.86
    -151.51 (-0.77%)
     
  • AIM

    752.67
    -2.02 (-0.27%)
     
  • GBP/EUR

    1.1655
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.2492
    +0.0029 (+0.23%)
     
  • Bitcoin GBP

    51,018.11
    -1,715.89 (-3.25%)
     
  • CMC Crypto 200

    1,376.09
    -6.49 (-0.47%)
     
  • S&P 500

    5,010.40
    -61.23 (-1.21%)
     
  • DOW

    37,807.47
    -653.45 (-1.70%)
     
  • CRUDE OIL

    82.38
    -0.43 (-0.52%)
     
  • GOLD FUTURES

    2,333.50
    -4.90 (-0.21%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,833.74
    -254.96 (-1.41%)
     
  • CAC 40

    7,974.44
    -117.42 (-1.45%)
     

3 Beaten-Down Genomics Stocks: Can They Recover?

3 Beaten-Down Genomics Stocks: Can They Recover?

All three of these companies can test for COVID-19, but they're well-suited to produce steadier revenue in ways that have nothing to do with coronaviruses. Exact Sciences' (NASDAQ: EXAS) stock price has tumbled around 41% since its high watermark this February. Screening for cancer is this company's bread and butter, but rapidly rising COVID-19 testing revenue excited investors enough to drive the stock to new all-time highs earlier this year.